Ziapin2 effectively restores retinal function in preclinical models of retinitis pigmentosa and macular degeneration
A multidisciplinary team of researchers from the Istituto Italiano di Tecnologia (IIT-Italian Institute of Technology) and ...
FIU News4d
Promising new drug candidate for Alzheimer’s
Kyung Bo Kim discovered compounds that improved cognitive function regardless of amyloid plaque buildup — an encouraging sign ...
FDA Accepts Astellas Pharma's Revised SNDA For IZERVAY In Geographic Atrophy Treatment
Astellas Pharma Inc. (ALPMY, ALPMY) announced that the U.S. Food and Drug Administration accepted the revised supplemental New Drug ...
Pharmabiz16h
Health Canada authorizes Roche’s Vabysmo pre-filled syringe for three leading causes of vision loss
Mississauga, Ontario Tuesday, January 21, 2025, 14:00 Hrs [IST] ...
ExtremeTech on MSN5h
Smart Glasses Mimic Insect Eyes to Assist the Visually Impaired With Macular Degeneration
These glasses allow people with macular degeneration to see complete objects by banishing pesky blind spots using dozens of ...
ophthalmologytimes4d
Ocugen doses first patient in phase 1 trial of OCU200 for treatment of diabetic macular edema
The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...
Monthly Prescribing Reference5d
Trial Results to Prompt BLA Resubmission for Intravitreal Formulation of Bevacizumab
ONS-5010 is an investigational ophthalmic formulation of bevacizumab, a vascular endothelial growth factor inhibitor, under development as an intravitreal injection.